Greenwich LifeSciences, Inc ARS, filed Oct 26, 2026

Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences is enrolling patients in Phase III Flamingo-01, evaluating GLSI-100 to prevent breast cancer recurrence, and expanding into Europe with plans for up to 150 sites globally. It needs significant additional financing for operations and product development. AI summary